Business StandardCadila to sell cheaper lung cancer drug in India by DecBusiness StandardMycidac-C is for patients suffering from non-small cell lung cancer (NSCLC). Modi said the drug test showed it improved survival possibilities by 28.2 per cent and…
Newstrack India |
Cadila Pharma launches new lung cancer drug
The Hindu The new drug has been licensed and approved by the Drug Controller General of India (DCGI). Mycidac-C is meant for patients suffering from non-small cell lung cancer (NSCLC). “The drug is affordable, and is many times cheaper than what out competitors … Ancestor of TB germ to fight lung cancerCalcutta Telegraph Cadila Pharma launches affordable drugs for lung cancerNewstrack India Cadila launches low-cost cancer drugTimes of India Jagran Josh –India.Com Health all 22 news articles » |
|
Cadila Pharma to debut novel lung cancer drug Mycidac-C in India
The Pharma Letter Cadila Pharmaceuticals, one of India’s largest privately-held pharmaceuticals company, has launched for the first time in the world, Mycidac-C, an affordable, unique and innovative drug for the treatment of lung cancer. Mycidac-C is an innovative … |
Cadila launches novel therapy for lung cancerTimes of IndiaMycidac-C is an innovative research product for patients suffering from a cancer sub-type, non-small cell lung cancer, and will be priced at Rs 4,000 for 10 injections. The total cost of therap…
|
Cadila launches Mycidac-C for treatment of lung cancer
NetIndian “Mycidac-C is an innovative research product for the patients suffering from Non Small Cell Lung Cancer (NSCLC). The drug has been approved for launch in India by the Drug Controller General of India (DCGI). It targets Desmocolin-3, a novel target … |
|
Cadila Pharmaceuticals launches lung cancer drug
Economic Times As per the company’s statement, Mycidac-C is an innovative research product for the patients suffering from Non Small Cell Lung Cancer (NSCLC). The drug has been approved for launch in India by the Drug Controller General of India (DCGI). It targets … |
|
Cadila unveils lung cancer drug priced at Rs 40000 for 10 shots
Hindu Business Line According to the World Health Organization (WHO), 1.25 million people are diagnosed with lung cancer annually. “This is the first novel product for cancer management from India,” Modi said, adding that “hundreds of crores” have been spent in developing … |
Business Standard (blog)Cadila Pharma launches affordable lung cancer drugBusiness Standard (blog)Ahmedabad-based Cadila Pharmaceuticals Limited, a privately held pharma company, has launched the Mycidac-C, an affordable, unique and innovative drug for…
The New Indian ExpressTraining, infrastructure can control chronic obstructive pulmonary disease …Times of IndiaPUNE: Despite the growing burden of chronic obstructive pulmonary disease (COPD), a progressive respiratory illness prevalent in the count…
|
Chronic Obstructive Pulmonary Disease could be a silent killer, warn Kanpur …
Times of India KANPUR: Pollution combined with an unbalanced lifestyle is a major cause of rising cases of Chronic Obstructive Pulmonary Disease (COPD), doctors said on World COPD Day on Wednesday. Emphasizing on the theme of the year, ‘It’s not too late”, they … |